Colistin and carbapenems have been considered as last-line antibiotics against serious infections caused by multidrug-resistant Gram-negative bacteria. However, public health concern has intensified from instances of colistin- and carbapenem-resistant *Enterobacteriaceae* infections increasingly reported worldwide.[@CIT0001]--[@CIT0003] Particularly, the coexistence of transferable New Delhi metallo-β-lactamase (NDM)-encoding gene *bla*~NDM~ and mobile colistin resistance gene *mcr* in *Enterobacteriaceae* poses a serious threat to global health, as its extensive spread could lead to outbreaks of untreatable infections.[@CIT0002],[@CIT0003] In this study, we characterized a clinical strain of *Klebsiella pneumoniae*, co-harboring *mcr-1* and *bla*~NDM-4~ resistance genes in Vietnam.

*K. pneumoniae* strain PI15KP27 was recovered from the sputum of a less than one-year-old patient admitted to a pediatric hospital in Ho Chi Minh City, Vietnam in 2015 with a diagnosis of pneumonia on day 21 after hospital admission. The child, still experiencing diarrhea, sepsis and severe pneumonia, was discharged from the hospital at the request of his family after staying in the intensive care unit and respiratory department for 34 days. During his hospitalization, the child was treated with metronidazole, levofloxacin, meropenem, and colistin. PI15KP27 was likely a hospital-acquired strain because it was identified more than two days after hospitalization.

Antimicrobial susceptibility evaluations of *K. pneumoniae* PI15KP27, recipient *E. coli* J53Az^R^ and transconjugants were performed by disk diffusion and agar dilution method according to the guidelines of Clinical and Laboratory Standards Institute (CLSI, 2018), except fosfomycin, which was interpreted by the European Union Committee for Antimicrobial Susceptibility Testing (EUCAST, 2019). Minimum inhibitory concentrations (MICs) for colistin and tigecycline were determined by broth microdilution method using guidelines of the EUCAST and the United States Food and Drug Administration (FDA), respectively. The results showed that PI15KP27 was resistant to 23 antibiotics which belonged to 17 classes, including last-resort antibiotics such as carbapenems (MICs ≥128 μg/mL) and colistin (MIC =32 μg/mL). It was intermediate resistance to amikacin (MIC =32 μg/mL) and susceptible to tigecycline (MIC =1 μg/mL) ([Table 1](#T0001){ref-type="table"}).Table 1Antimicrobial Susceptibility Of Clinical Strain PI15KP27, Recipient *E. Coli* J53Az^R^ And Its TransconjugantsAntimicrobial SusceptibilityPI15KP27TransconjugantsJ53pKP27-MCR1pKP27-NDM4**Disk Diffusion assay**ResistantGM, TOB, K, ETP, IMP, MEM, CXM, CAZ, FEP, FOX, CIP, SXT, ATM, AMP, AUG, C, TE, AZ, S, FC, S, TEGM, TOB, K, ETP, IMP, MEM, CXM, CAZ, FEP, FOX, AMP, AUG--IntermediateAMPCIPAMPSusceptible--GM, TOB, K, ETP, IMP, MEM, CXM, CAZ, FEP, FOX, CIP, SXT, ATM, AUG, AZ, FSXT, ATM, C, TE, AZ, S, FGM, TOB, K, ETP, IMP, MEM, CXM, CAZ, FEP, FOX, CIP, SXT, ATM, AUG, C, TE, AZ, S, F**Minimum inhibitory concentration (μg/mL)**Antimicrobial classAntimicrobial agentAminoglycosidesGM\>2562481.5AK322322CarbapenemsETP\>1280.008320.008IMP1280.125160.125MEM\>1280.01580.015Extended-spectrum cephalosporins; 3rd and 4th generation cephalosporinsCTX\>2560.125\>2560.125CAZ\>2560.25\>2560.25FEP\>256\<0.01680.016CephamycinsFOX\>2568\>2568FluoroquinolonesCIP\>2560.030.50.015Folate pathway inhibitorsSXT320.050.0320.05GlycylcyclinesTGC10.060.060.06PenicillinsAMP\>2563\>2564Penicillins + β-lactamase inhibitorsAUG\>2563483PhenicolsC\>25625644Phosphonic acidsFOS\>2560.50.50.5PolymyxinsCS3240.50.5TetracyclinesTE\>25612822[^2]

The whole-genome sequencing was carried out using the MinION nanopore sequencer (Oxford Nanopore Technologies, UK). Genome assembly was performed by Canu 1.6[@CIT0004] and then corrected using Pilon 1.22[@CIT0005] with reads obtained from 250-bp paired-end Illumina MiSeq sequencing (Illumina Inc., USA). Genetic analysis of the complete genome sequence indicated that PI15KP27 consisted of a 5,247,824-bp chromosome with an average 50.1% GC content and three plasmids pKP27-MCR1, pKP27-NDM4 and pKP27-MPH with a sequencing depth of 110. Identification of antimicrobial resistance genes using the ResFinder 3.0 database ([<https://cge.cbs.dtu.dk/services/ResFinder/>]{.ul}) revealed the presence of 29 resistance genes, most of them located on three plasmids ([Table 2](#T0002){ref-type="table"}). Particularly, the *mcr-1* gene was found on a 144,138-bp IncA/C2-type plasmid pKP27-MCR1 and *bla*~NDM-4~ was found on a 121,851-bp IncFIIK-type plasmid pKP27-NDM4, which were able to be transferred into the recipient *E. coli* strain J53 by conjugation assays.Table 2Genomic Characteristics Of *K. Pneumoniae* PI15KP27ChromosomePlasmidspKP27-MPHpKP27-MCR1pKP27-NDM4Accession no.CP041639CP041640CP041641CP041642Sequence type/Plasmid replicon typeST-16IncFIB(K)IncA/C2IncFII(K)Size (bp)5,247,824222,330144,138121,851Resistance genes*bla*~SHV-1~,*oqxB, oqxA, fosAaac(6ʹ)-Ib-cr, aadA2, bla*~OXA-1~,*bla*~CTX-M-15~, *bla*~TEM-1B~, *aac(6ʹ)-Ib-cr, mph*(A), *catB4, sul1, tet*(A), *dfrA12aph(6)-Id, aph(3ʹ')-Ib, mcr-1, floR, sul2, tet*(A)*aac(3)-Iid, aadA1, aac(6ʹ)-Ib, bla*~NDM-4~,*bla*~CTX-M-14~, *bla*~OXA-9~,*aac(6ʹ)-Ib-cr, qnrS1*

Sodium azide-resistant *E. coli* J53Az^R^ strain was used as the recipient for the conjugation experiments to examine the transferability of plasmids in the clinical strain. A total of 1ml of each clinical donor and recipient culture was mixed together and incubated at 37°C for 6h. Transconjugants were selected on brain-heart infusion agar (BHIA) (Difco) containing sodium azide (100 μg/mL) plus imipenem (1 μg/mL), colistin (4 μg/mL), or azithromycin (20 μg/mL). As a result, transconjugants selected on the imipenem supplemented medium or colistin supplemented medium showed antimicrobial susceptibility profiles compatible with resistant phenotypes encoded by genes located on plasmid pKP27-NDM4 (*aac(3)-Iid, aadA1, aac(6ʹ)-Ib, bla*~NDM-4~,*bla*~CTX-M-14~, *bla*~OXA-9~,*aac(6ʹ)-Ib-cr, qnrS1*) and pKP27-MCR1 (*mcr-1, floR, sul2, tet*(A)), respectively ([Table 2](#T0002){ref-type="table"}). In particular, transconjugants selected on imipenem supplemented medium showed resistant to gentamicin, tobramycin, kanamycin, ertapenem, imipenem, meropenem, cefuroxime, cefotaxime, ceftazidime, cefepime, cefoxitin, ampicillin, amoxicillin-clavulanic acid; intermediate to ciprofloxacin and susceptible to trimethoprim-sulfamethoxazole, aztreonam, chloramphenicol, tetracycline, azithromycin, sulfonamides, nitrofurantoin. Transconjugants selected on colistin supplemented medium showed resistant to colistin, chloramphenicol, sulfonamides, tetracycline; intermediate to ampicillin and susceptible to other above remain antibiotics ([Table 1](#T0001){ref-type="table"}). There was no strain selected on azithromycin supplemented medium. The presence of *mcr-1* and *bla*~NDM4~ in the transconjugants was confirmed by PCR. These results illustrated that *mcr-1* and *bla*~NDM-4~ genes were carried by different self-conjugative plasmids.

There was a significant difference in minimal inhibitory concentration (MIC) for colistin of the clinical strain (MIC =32 μg/mL) in comparison to its transconjugant carrying *mcr-1* positive plasmid (MIC =4 μg/mL), indicating that colistin resistance of this strain was conferred by *mcr-1* and additional chromosomal resistance determinants. Eight amino acid substitutions were identified by comparison to the genome of *K. pneumoniae* HS11286 (GenBank accession no. CP003200), including E57G in PmrA; G248R in PmrB; C27F and Q330R in PmrC; I260L in PmrI; V53I, I94L and I300V in PmrJ, all proteins that are involved in lipopolysaccharide modifications, may be associated with colistin resistance. All those mutations, except G248R and Q330R, were earlier observed in some colistin-resistant *K. pneumoniae* isolates.[@CIT0006]--[@CIT0009] Further research is required to clarify the significance of these mutations in colistin resistance. The complete sequences of *K. pneumoniae* strain PI15KP27 and three plasmids have been deposited in GenBank under the accession numbers CP041639-CP041642.

The result of multilocus sequence typing (MLST) using MLST1.8 database ([<https://cge.cbs.dtu.dk/services/MLST/>]{.ul}) indicated that PI15KP27 belonged to sequence type 16 (ST16). This clone has disseminated worldwide with different antimicrobial resistance profiles, which was reported as a β-lactamase producer or involved in outbreaks of CTX-M-15-producing *K. pneumoniae*.[@CIT0010],[@CIT0011] Additionally, the ST16 clone was also found in some carbapenem-resistant *K. pneumoniae* isolates spread in a clinical setting in Vietnam.[@CIT0012] ST16 may become a high-risk clone causing multidrug-resistant hospital-acquired infections.[@CIT0011] The MLST results in this study support this assumption.

The coexistence of *mcr* and *bla*~NDM~ has been commonly identified in *E. coli* but rarely noted in *K. pneumoniae*.[@CIT0013] The co-harboring of those genes was reported in *K. pneumoniae* isolates from both livestock and human clinical samples.[@CIT0002],[@CIT0003] To the best of our knowledge, this was the first report in Vietnam of co-production of MCR and NDM in a clinical *K. pneumoniae* strain.

The accumulation of multiple antibiotic resistance mechanisms in this clinical isolate raises alarm on potential spread of extensively drug-resistant *K. pneumoniae* in healthcare settings. The genomic epidemiology surveillance of hospital-acquired infection pathogens, including colistin- and carbapenem-resistant *K. pneumoniae*, is highly necessary to prevent their dissemination.
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